Elixir Medical
Developer of catheter-delivered vascular technologies for treatment of coronary and peripheral artery disease. Public materials describe design and development of implantable vascular scaffolds and catheter delivery systems, localized site-specific drug-delivery therapies for percutaneous coronary intervention (PCI), clinical evidence generation including randomized controlled trials, and global regulatory and quality systems management. Headquarters and contact details are provided for Milpitas, CA, USA.
Industries
Nr. of Employees
medium (51-250)
Elixir Medical
Patents
Products
Drug-eluting coronary scaffold (implantable)
An implantable metallic scaffold combined with a biodegradable polymer drug coating designed to permit timed resorption of the coating and mechanical unlocking of the scaffold to support adaptive vessel remodeling while maintaining temporary structural support.
Contact lithotripsy catheter for vascular calcium modification
A catheter-based lithotripsy device engineered to fracture vascular calcium using contact-based mechanical stress, designed to integrate with standard PCI workflow without requiring separate capital equipment.
Site-specific multi-drug antithrombotic therapy for PCI
A localized antithrombotic therapy intended for delivery at PCI sites that combines multiple agents to address thrombotic and bleeding risk associated with systemic regimens.
Drug-eluting coronary scaffold (implantable)
An implantable metallic scaffold combined with a biodegradable polymer drug coating designed to permit timed resorption of the coating and mechanical unlocking of the scaffold to support adaptive vessel remodeling while maintaining temporary structural support.
Contact lithotripsy catheter for vascular calcium modification
A catheter-based lithotripsy device engineered to fracture vascular calcium using contact-based mechanical stress, designed to integrate with standard PCI workflow without requiring separate capital equipment.
Site-specific multi-drug antithrombotic therapy for PCI
A localized antithrombotic therapy intended for delivery at PCI sites that combines multiple agents to address thrombotic and bleeding risk associated with systemic regimens.
Expertise Areas
- Coronary and peripheral vascular device development
- Localized drug-delivery strategies for PCI
- Clinical trial management and evidence generation (including RCTs)
- Regulatory compliance and quality management for medical devices
Key Technologies
- Drug-eluting implantable scaffolds
- Biodegradable polymer drug coatings
- Metallic scaffold architectures
- Localized multi-drug vascular delivery
News & Updates
Randomized controlled trial (BIOADAPTOR-RCT) reporting 12-month clinical and imaging data comparing a bioadaptor scaffold to a drug-eluting stent, including measurements of in-device pulsatility and late lumen loss.
Randomized controlled trial (BIOADAPTOR-RCT) reporting 12-month clinical and imaging data comparing a bioadaptor scaffold to a drug-eluting stent, including measurements of in-device pulsatility and late lumen loss.